中华皮肤科杂志 ›› 2008, Vol. 41 ›› Issue (11): 726-728.

• 论著 • 上一篇    下一篇

趋化因子CCL22/CCR4在SLE发病中的作用

杨海琼 邓丹琪 金从国 张佩莲 周晓鸿   

  1. 大连市皮肤病医院 昆明医学院第二附属医院皮肤科 昆明医学院第二附属医院皮肤科
  • 收稿日期:2007-12-17 修回日期:2008-02-23 发布日期:2008-11-15
  • 通讯作者: 杨海琼 E-mail:zqy0312@yahoo.com.cn

Roles of the chemokine CCL22 and its receptor CCR4 in the pathogenesis of systemic lupus erythematosus

  

  • Received:2007-12-17 Revised:2008-02-23 Published:2008-11-15

PDF

116

摘要： 目的 探讨趋化因子CCL22及其受体CCR4在SLE发病中的作用和临床意义。方法 SLE患者48例和体检正常人26例为检测对象。采用酶联免疫吸附试验测定血浆中CCL22的浓度，流式细胞仪分析法测定外周血趋化因子受体CCR4的水平。结果 SLE患者血浆中CCL22的水平（227.03 ± 122.84 ng/L）较正常人对照组（369.53 ± 79.10 ng/L）降低（P < 0.05）；SLE患者有肾损组CCL22水平（168.0 ± 61.83 ng/L）较无肾损组（292.77 ± 163.45 ng/L）明显降低（P < 0.05）。SLE患者外周血中表达CCR4的细胞百分比（20.24% ± 13.86%）较正常人对照组（10.44% ± 3.07%）升高（P < 0.01），且CD3+CCR4+细胞百分比高于CD3-CCR4+细胞百分比。与正常人对照组比较，重度活动的SLE患者 CCL22水平降低（P ＜ 0.05），SLE患者CCR4的表达水平随着SLEDAI评分的升高而升高。SLE患者CCL22与SLEDAI评分呈负相关（r = -0.308，P < 0.05）。结论 CCL22/CCR4在SLE发生、发展及器官损害中可能起一定的作用。

关键词: 红斑狼疮, 系统性;趋化因子CCL22;受体, CCR4

Abstract: Objective To investigate the expression of cellular chemokine CCL22 and its receptor CCR4, as well as its clinical significance in systemic lupus erythematosus （SLE）, along with its roles in the pathogenesis of this disease. Methods Forty-eight patients with SLE and 26 normal human controls were recruited into this study. The patient cohort included 2 males and 46 females with an average age of 33.98 ± 12.73 years and disease course of 1 month to 20 years. Blood samples were collected from the subjects. ELISA and flow cytometry were used to examine the plasma concentration of CCL22 together with the CCR4 expression on peripheral blood cells. SLEDAI was applied to evaluate the severity of SLE patients. Results The plasma concentration of CCL22 was 227.03 ± 122.84 ng/L in SLE group, 369.53 ± 79.10 ng/L in the control group, 168.09 ± 61.83 ng/L in patients with lupus nephritis and 292.77 ± 163.45 ng/L in patients without lupus nephritis; there was a significant difference between the SLE patients and normal controls （P < 0.05） as well as between patients with lupus nephritis and those without （P < 0.05）. Increased percentage of CCR4-expressing cells were observed in the peripheral blood of patients with SLE compared with the controls （20.24% ± 13.86% vs 10.44% ± 3.07%, P < 0.01）, and the percentage of CD3+CCR4+ cells was significantly higher than that of CD3-CCR4+ cells. Moreover, a decrease was noted in the plasma concentration of CCL22 in severe patients （P < 0.05）. In SLE patients, the percentage of CCR4 increased with the rise in SLEDAI score, whereas the plasma concentration of CCL22 negatively correlated with SLEDAI score （r = -0.308, P < 0.05）. Conclusion CCL22/CCR4 may play a certain role in the development, progression and organ involvement in SLE.